Intravitreal injection of anti-vascular endothelial growth factor (VEGF) agents is widely regarded as the standard of care for patients with retinal disease, including neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and macular edema (ME) due to retinal vein occlusion (RVO), and has become the most commonly performed ophthalmic procedure. This evidence concerns the gene VEGFA and macular retinal edema.